137 related articles for article (PubMed ID: 33451072)
1. Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients.
Piciu A; Piciu D; Polocoser N; Kovendi AA; Almasan I; Mester A; Morariu DS; Cainap C; Cainap SS
Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33451072
[TBL] [Abstract][Full Text] [Related]
2.
Ulaner GA; Juarez J; Riedl CC; Goldman DA
J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
[No Abstract] [Full Text] [Related]
3. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
4.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
7. Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer.
Liu Y
World J Clin Oncol; 2014 Dec; 5(5):982-9. PubMed ID: 25493234
[TBL] [Abstract][Full Text] [Related]
8. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes.
Jeong YJ; Kang DY; Yoon HJ; Son HJ
Breast Cancer Res Treat; 2014 May; 145(1):137-42. PubMed ID: 24682676
[TBL] [Abstract][Full Text] [Related]
9. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.
Chakraborty D; Basu S; Ulaner GA; Alavi A; Kumar R
PET Clin; 2018 Jul; 13(3):355-361. PubMed ID: 30100075
[TBL] [Abstract][Full Text] [Related]
11. The role of FDG PET/CT in detection of distant metastasis in theinitial staging of breast cancer.
Aliyev A; Yilmaz Aksoy S; Özhan M; Ekmekçioğlu Ö; Vatankulu B; Kocael PÇ; Sağer MS; Erkan ME; Sönmezoğlu K; Halaç M
Turk J Med Sci; 2016 Feb; 46(2):349-60. PubMed ID: 27511496
[TBL] [Abstract][Full Text] [Related]
12. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
Taneja S; Jena A; Goel R; Sarin R; Kaul S
Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
[TBL] [Abstract][Full Text] [Related]
14. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
15. Up-front F18-FDG PET/CT in suspected salivary gland carcinoma.
Westergaard-Nielsen M; Rohde M; Godballe C; Eriksen JG; Larsen SR; Gerke O; Nguyen N; Nielsen MK; Nielsen AL; Thomassen A; Asmussen JT; Diaz A; Høilund-Carlsen PF; Bjørndal K
Ann Nucl Med; 2019 Aug; 33(8):554-563. PubMed ID: 31102059
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
17. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
18. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
20. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients.
Fehr M; Müller J; Knitel M; Fornaro J; Horber D; Koeberle D; Cerny T; Güller U
Clin Colorectal Cancer; 2017 Dec; 16(4):343-348. PubMed ID: 28412138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]